ADMA Biologics (ADMA) shares have skyrocketed 275.7% in a year against the industry’s decline of 14.3%. The stock has also outperformed the sector and the S&P 500 during the aforementioned period.ADMA also hit a 52-week high of $23.64 on Nov. 11. The stupendous rally can be attributed to the company’s consistently strong quarterly performance and raised guidance.ADMA Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchAsceniv’s Performance Fuels ADMA’s GrowthADMA Biologics markets p ...